GC Biopharma USA, Inc.

GC Biopharma has been delivering plasma-derived therapeutics to patients worldwide for more than 50 years. We are a family-founded company with a steadfast commitment to providing safe and effective therapies to those in need. Our US leadership team of healthcare professionals brings a wealth of experience from the plasma industry fueled by a strong commitment to collaboration. As physicians, pharmacists and nurses, we possess firsthand knowledge of patients’ and partners’ needs, allowing us to create meaningful solutions together. By promoting a culture of ongoing learning and innovation, we aim to address the most pressing healthcare challenges while anticipating and preparing for future needs. We are dedicated to advancing scientific research and treatment breakthroughs, with more than 500 people in our R&D workforce, and more than 11% of our revenue invested in R&D annually. There are three core areas in our R&D portfolio: plasma-derived therapies, vaccines and rare diseases. GC Biopharma established GC Biopharma USA in 2016, with its US IVIG (IV immunoglobulin) sales, marketing and business operations based in Teaneck, N.J. Our global footprint includes offices in South Korea (headquarters), Japan, Vietnam, Brazil and the United States. GC Biopharma distributes specialty pharmaceuticals in more than 50 countries.